GLP-1 medicines and bone health — what the DXA sub-studies show

What the concern is

Bone is a mechanically responsive tissue — mechanical loading from body weight and muscle contraction is one of several factors that help maintain bone mineral density, alongside hormonal, nutritional and genetic factors. Rapid, substantial weight loss from any cause has been associated in published research with reductions in bone mineral density, plausibly reflecting reduced mechanical loading combined with other weight-loss-related metabolic changes. Because semaglutide and tirzepatide can produce large-magnitude weight loss relatively efficiently, researchers have examined whether this same pattern applies to pharmacologically induced weight loss, alongside the separately studied question of lean-mass loss during GLP-1 therapy.

What the DXA sub-studies show

A limited number of published sub-studies within the STEP and SURMOUNT trial programmes have incorporated DXA scanning in a subset of participants to measure bone mineral density alongside the primary body-composition outcomes reported in the main trials. These sub-studies generally report measurable reductions in BMD at sites such as the hip accompanying substantial total weight loss, though sample sizes for the bone-specific analyses are typically smaller than the main trial cohorts, and the clinical significance of the observed reductions — in terms of actual fracture risk — is not yet well characterised in the published literature. This remains a comparatively under-studied area relative to the broader body-composition literature covered in GLP-1 and lean mass.

The older-adult and osteoporosis-history overlay

Older adults generally carry a higher baseline fracture risk than younger adults, reflecting age-related bone density decline and, in postmenopausal women, the accelerated bone loss associated with reduced oestrogen levels. This background risk exists independently of GLP-1 therapy, but it means that any additional BMD reduction associated with rapid weight loss could plausibly be of greater clinical relevance in an older adult with lower bone density reserve than in a younger adult, even if the proportionate BMD change were similar. See sarcopenic obesity and lean mass for the related muscle-and-ageing discussion. Individuals with an existing diagnosis of osteoporosis or osteopenia, or a prior fragility fracture, represent a population where clinicians may pay closer attention to bone health during GLP-1 therapy, though this remains an area of clinical judgement rather than a standardised, published monitoring protocol.

Practical monitoring considerations

There is no standardised, published requirement for routine DXA scanning before or during GLP-1 therapy for the general population. Decisions about baseline or on-treatment bone-density assessment are individualised, generally informed by risk factors such as age, menopausal status, fracture history and known bone-health diagnoses, and made by the prescriber managing treatment. General bone-health literature — not specific to GLP-1 therapy — identifies weight-bearing exercise, resistance training and adequate calcium and vitamin D intake as supportive measures during any period of significant weight loss; this page reports that general principle without prescribing an individual regimen.

What the evidence does not establish

Published DXA sub-study data on GLP-1-related bone-density change are limited in volume, drawn from sub-analyses of a small number of trials rather than a dedicated, purpose-built bone-outcomes research programme. Critically, a measured reduction in bone mineral density does not, on its own, establish a proportionate increase in actual fracture risk — that link requires longer-term outcome data that are not yet mature for this class of medicine. Comparative data across different GLP-1 and dual-agonist molecules, and long-term data beyond the duration of the pivotal trials, remain limited, and none of the published sub-studies were originally designed with bone-density change as their primary pre-specified outcome, which further limits how confidently the findings can be generalised. This page does not provide individual screening recommendations, fracture-risk calculations, or supplementation guidance — these require assessment by a GP or bone-health specialist familiar with an individual's full clinical picture.

Frequently asked questions

Does Ozempic or Mounjaro cause bone loss?

Rapid, substantial weight loss from any cause — including GLP-1 or dual-agonist therapy, caloric restriction, and bariatric surgery — is associated with reductions in bone mineral density (BMD) in published research, reflecting reduced mechanical loading on the skeleton and other weight-loss-related physiological changes. This is not evidence of a direct toxic effect of GLP-1 pharmacology on bone cells; it reflects a general pattern seen across substantial weight-loss interventions. Whether this BMD reduction translates into a meaningfully increased fracture risk for most patients is not yet well established and is an area of ongoing research interest.

What do the DXA sub-studies actually show?

A limited number of published sub-studies within the STEP and SURMOUNT trial programmes have used DXA (dual-energy X-ray absorptiometry) scanning in a subset of participants to measure bone mineral density alongside the primary body-composition outcomes. These sub-studies generally report some reduction in BMD at hip and other measured sites accompanying substantial weight loss, though the magnitude and clinical significance are still being characterised, and sample sizes in the bone-specific sub-analyses are typically smaller than the main trial populations.

Is bone loss on GLP-1 therapy the same as osteoporosis?

No. A measured reduction in bone mineral density on a DXA scan is not the same as a clinical diagnosis of osteoporosis, which involves specific diagnostic thresholds (T-scores) and clinical context. Published GLP-1 sub-study data describe average BMD changes at a population level within trial cohorts; they do not establish that any individual patient has developed osteoporosis as a result of treatment. Individual bone health assessment requires clinical evaluation, not extrapolation from trial-level averages.

Are older adults at greater risk?

Older adults generally have lower baseline bone density and a higher baseline fracture risk than younger adults, independent of any GLP-1 therapy, due to age-related bone loss and, in postmenopausal women, oestrogen-related bone density decline. Because GLP-1 and dual-agonist therapy can produce substantial weight loss relatively efficiently, clinicians and researchers have raised the question of whether older adults — particularly those with existing osteoporosis or osteopenia — merit closer attention to bone health during treatment, though defined monitoring protocols specific to GLP-1 therapy are not yet standardised.

Does a history of osteoporosis mean I shouldn't take a GLP-1 medicine?

This is an individual clinical decision that weighs the metabolic benefits of treatment against bone-health considerations for that specific patient, made by the prescriber managing the person's overall care, ideally in consultation with a bone-health specialist where relevant. This page does not provide a recommendation for or against treatment in people with a history of osteoporosis or osteopenia — that assessment requires an individual clinical picture this page cannot see.

Is bone loss related to the lean-mass loss also seen with GLP-1 therapy?

Muscle and bone are mechanically and physiologically linked — muscle contraction provides mechanical loading that helps maintain bone density, and some of the hormonal and nutritional factors associated with rapid weight loss affect both tissue compartments. Research into GLP-1-related lean-mass loss and bone-density change often discusses the two as related aspects of body-composition change during rapid weight loss, though they are measured and reported separately in most published sub-studies. See the GLP-1 and lean mass page and the lean-mass preservation mechanism page for the related discussion.

What can be done to support bone health during GLP-1 therapy?

Published general bone-health literature — not GLP-1-specific research — identifies weight-bearing exercise, resistance training, and adequate calcium and vitamin D intake as supportive strategies for maintaining bone density during any period of weight loss. This page reports that general evidence base; it does not prescribe an individual supplementation or exercise plan, which should be tailored to individual circumstances, ideally with input from a GP, dietitian or bone-health specialist.

Should I have a DXA scan before starting a GLP-1 medicine?

This is a clinical decision for the prescriber managing treatment, generally informed by individual risk factors such as age, menopausal status, prior fracture history, and known osteoporosis or osteopenia, rather than a routine requirement applied to everyone starting therapy. This page does not recommend universal baseline DXA scanning and does not set out a specific monitoring protocol.

Does bone density recover after stopping a GLP-1 medicine?

Published data specifically tracking bone-density recovery after GLP-1 discontinuation are limited. Weight regain, which is commonly observed after stopping GLP-1 therapy, could plausibly be associated with some recovery of mechanical loading on bone, but this has not been extensively characterised as a discrete outcome in trial extension or discontinuation studies, and should not be assumed without direct evidence.

Does this apply to all GLP-1 and dual-agonist medicines equally?

Published bone-density sub-study data exist for a limited number of specific trials within the semaglutide and tirzepatide programmes; head-to-head bone-density comparisons using consistent methodology across all licensed and investigational molecules are not available. The general pattern — some BMD reduction accompanying substantial weight loss — is a plausible class-level consideration given the shared mechanism of large-magnitude weight loss, but molecule-specific data remain limited outside the specific published sub-studies.